BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Niu ZS, Niu XJ, Wang M. Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol 2015; 7(1): 7-27 [PMID: 25624992 DOI: 10.4254/wjh.v7.i1.7]
URL: https://www.wjgnet.com/1948-5182/full/v7/i1/7.htm
Number Citing Articles
1
Zhen Long Ng, Jiamin Siew, Jia Li, Guanxu Ji, Min Huang, Xiaohua Liao, Sue Yu, Yuanyuan Chew, Chin Wen Png, Yongliang Zhang, Shijun Wen, Henry Yang, Yiting Zhou, Yun Chau Long, Zhi Hong Jiang, Qiang Wu. PATZ1 (MAZR) Co-occupies Genomic Sites With p53 and Inhibits Liver Cancer Cell Proliferation via Regulating p27Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.586150
2
Xiaodong Wang, Dongying Chen, Bin Chen. The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular CarcinomasAcademic Radiology 2020; 27(12): 1720 doi: 10.1016/j.acra.2018.04.021
3
Ganbin Qiu, Jincan Chen, Weixiong Liao, Yonghui Liu, Zhongyan Wen, Yue Zhao. Gadoxetic acid-enhanced MRI combined with T1 mapping and clinical factors to predict Ki-67 expression of hepatocellular carcinomaFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1134646
4
Changwu Zhou, Xiaoyan Ni, Xin Lu, Yi Wang, Xianling Qian, Chun Yang, Mengsu Zeng. MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-CholangiocarcinomaJournal of Hepatocellular Carcinoma 2021; : 975 doi: 10.2147/JHC.S325686
5
Veysi Hakan YARDIMCI, Süheyla EKEMEN, Abdullah Yüksel BARUT. Safra Kesesi Adenomyomatozisi Prekanseröz Lezyon mudur? Ki-67 ve P53 Pozitif Ekspresyonunun Normal Safra Kesesi Dokusu ile Karşılaştırılmasıİstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi 2022; (18): 1041 doi: 10.38079/igusabder.1033234
6
Jia Li, Yunhui Ma, Chunyu Yang, Ganbin Qiu, Jingmu Chen, Xiaoliang Tan, Yue Zhao. Radiomics analysis of R2* maps to predict early recurrence of single hepatocellular carcinoma after hepatectomyFrontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1277698
7
Amr Abdel-Moety, Nahed Baddour, Perihan Salem, Hesham El-Tobgy, Assem El-Shendidi. SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency AblationJournal of Clinical and Experimental Hepatology 2022; 12(3): 774 doi: 10.1016/j.jceh.2021.12.001
8
Da-Wei Sun, Lin An, Feng Wei, Lin Mu, Xiao-Ju Shi, Chuan-Lei Wang, Zheng-Wei Zhao, Teng-Fei Li, Guo-Yue Lv. Prognostic significance of parameters from pretreatment 18F-FDG PET in hepatocellular carcinoma: a meta-analysisAbdominal Radiology 2016; 41(1): 33 doi: 10.1007/s00261-015-0603-9
9
Zhiqing Mo, Hao Ding, Xiaojiao Zhou, Zisan Zeng, Liling Long. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1Abdominal Radiology 2022; 47(1): 209 doi: 10.1007/s00261-021-03325-z
10
HONG-JUN LI, QI-MAN SUN, LONG-ZI LIU, JUN ZHANG, JUN HUANG, CHENG-HONG WANG, RUI DING, KANG SONG, ZHONG TONG. High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcomeOncology Reports 2015; 34(2): 795 doi: 10.3892/or.2015.4060
11
Aloísio Felipe-Silva, Alda Wakamatsu, Cinthya dos Santos Cirqueira, Venâncio Avancini Ferreira Alves. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy casesWorld Journal of Gastroenterology 2016; 22(27): 6246-6256 doi: 10.3748/wjg.v22.i27.6246
12
Hui Xiong, Yuan-Lin Zeng. Standard-b-Value Versus Low-b-Value Diffusion-Weighted Imaging in Hepatic Lesion DiscriminationJournal of Computer Assisted Tomography 2016; 40(3): 498 doi: 10.1097/RCT.0000000000000377
13
Marie Lequoy, Christèle Desbois‐Mouthon, Dominique Wendum, Vandana Gupta, Jean‐Luc Blachon, Olivier Scatton, Sylvie Dumont, Mireille Bonnemaire, Fabien Schmidlin, Olivier Rosmorduc, Laetitia Fartoux. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosisHistopathology 2017; 70(3): 492 doi: 10.1111/his.13034
14
Haoyu Sun, Jing Xu, Mei Huang, Qiang Huang, Rui Sun, Weihua Xiao, Cheng Sun. CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinomaImmunology Letters 2016; 178: 105 doi: 10.1016/j.imlet.2016.08.009
15
M. A. Abdelwa, M. M. Elbedew, A. M. Amin, A. K. Tawfik. Serum Endoglin and IL-6 Levels as Complementary Diagnostic Biomarkers for Hepatocellular Carcinoma in Egyptian Liver Cirrhosis PatientsResearch Journal of Immunology 2016; 10(1): 1 doi: 10.3923/rji.2017.1.7
16
Xin-Xing Hu, Wen-Tao Wang, Li Yang, Zhao-Xia Yang, He-Yue Liang, Ying Ding, Yuan Ji, Meng-Su Zeng, Sheng-Xiang Rao. MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomasEuropean Journal of Radiology 2019; 113: 7 doi: 10.1016/j.ejrad.2019.01.036
17
Xin Yuan, Yize Zhang, Zujiang Yu. Expression and clinical significance of miR-3615 in hepatocellular carcinomaJournal of International Medical Research 2021; 49(1) doi: 10.1177/0300060520981547